ProCE Banner Activity

Identification and Management of Tardive Dyskinesia 2022

Slideset Download

This presentation on the identification and management of tardive dyskinesia 2022 reviews the relative prevalence of TD in patients with schizophrenia, mood spectrum disorders, and anxiety disorders; and the effective use of VMAT2 inhibitors without discontinuing other essential psychiatric treatments such as antipsychotics and antidepressants.

Released: May 11, 2022

Expiration: May 10, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Christoph U. Correll

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Professor of Child and Adolescent Psychiatry
Charité – Universitätsmedizin Berlin
Berlin, Germany

Robert O. Cotes

Robert O. Cotes, MD

Associate Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Jonathan M. Meyer

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This program is supported by educational grants from:

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Professor of Child and Adolescent Psychiatry
Charité – Universitätsmedizin Berlin
Berlin, Germany

Christoph U. Correll, MD, has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of Cardio Diagnostics, Mindpax, and LB Pharma.

Robert O. Cotes, MD

Associate Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Robert O. Cotes, MD: consultant/advisor/speaker: Saladax; researcher: Alkermes, Karuna, Otsuka, Roche.

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Jonathan Meyer, MD: consultant/advisor/speaker: Alkermes, AbbVie, Axsome, Bioexcel, Cervel, ITCI, Karuna, Neurocrine, Otsuka, Relmada, Sunovion, Teva.